Caption Management’s Viridian Therapeutics VRDN Stock Holding History

Caption Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.58M	Buy	86,040 +40,913	+91%	+$659K	0.01%	981
2026 Q1	$883K	Buy	+45,127	New	+$1.34M	0.01%	1062
2025 Q4	–	Sell	-8,956	Closed	-$193K	–	2094
2025 Q3	$193K	Buy	+8,956	New	+$162K	﹤0.01%	1474
2025 Q1	–	Sell	-56,760	Closed	-$967K	–	2084
2024 Q4	$1.09M	Buy	+56,760	New	+$1.23M	0.01%	891
2024 Q3	–	Sell	-44,300	Closed	-$724K	–	1607
2024 Q2	$576K	Buy	44,300 +19,300	+77%	+$267K	0.01%	783
2024 Q1	$438K	Buy	+25,000	New	+$485K	0.01%	900
2023 Q3	–	Sell	-36,000	Closed	-$856K	–	1571
2023 Q2	$856K	Buy	36,000 +21,000	+140%	+$539K	0.02%	697
2023 Q1	$382K	Buy	+15,000	New	+$481K	0.01%	840
2022 Q3	–	Sell	-17,777	Closed	-$206K	–	1875
2022 Q2	$206K	Buy	+17,777	New	+$239K	﹤0.01%	1232

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caption Management's VRDN Position: Q2 2026 in Review

Caption Management increased its Viridian Therapeutics (VRDN) stake by 91% in Q2 2026, buying an estimated $659K and bringing the position to 86,040 shares worth $1.58M. The position accounts for 0.01% of the portfolio, ranked #981.

Caption Management first reported a position in VRDN in Q2 2022 and has held it in 9 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Caption Management held 86,040 shares of Viridian Therapeutics worth $1.58M as of Q2 2026.
Caption Management bought 40,913 Viridian Therapeutics shares in Q2 2026, an estimated $659K.
Viridian Therapeutics made up 0.01% of Caption Management's portfolio in Q2 2026, its #981 holding.
Caption Management first reported a position in Viridian Therapeutics in Q2 2022 and has held it in 9 quarters since.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.